RxDoctor Payments Data

Rajeev Sharma, MD

Psychiatry · Hyannis, MANPI 1710309950

Payments from drug & device makers

$4,507in general payments, 2019–2025

Across 211 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$749
  • Johnson & Johnson$561
  • Alkermes, Inc.$551
  • Otsuka America Pharmaceutical, Inc.$526
  • Neurocrine Biosciences, Inc.$500
  • Teva Pharmaceuticals USA, Inc.$469
  • plus $1K from 10 others

What the payments were for

  • Food & beverage$4,26495%
  • Education$2435%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,507 in reported general payments places this provider in the 90th percentile of 1,431 psychiatry providers in Massachusetts.

See all psychiatry providers in Massachusetts

Medicare billing

Part B allowed, 2024
$41,514
Medicare patients
93
Services billed
499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate174$542,045
Abilify MaintenaAripiprazole62$161,546
AristadaAripiprazole Lauroxil12$25,496
VraylarCariprazine Hcl14$24,354
Aripiprazole148$18,228
Risperdal ConstaRisperidone Microspheres14$16,070
Clozapine185$13,063
Paliperidone ErPaliperidone44$7,868
Olanzapine225$6,726
Chlorpromazine Hcl22$4,292
Quetiapine Fumarate ErQuetiapine Fumarate18$4,074
Divalproex Sodium104$3,824
Fluphenazine Hcl27$3,801
Bupropion XlBupropion Hcl46$3,159
Risperidone244$3,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$561$558,115188 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$526$161,54662 claims
Alkermes, Inc.Aristada$551$25,49612 claims
AbbVieVraylar$464$24,35414 claims
Teva Pharmaceuticals USA, Inc.Loxapine$469$22824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,431 psychiatry providers in Massachusetts.

Other psychiatry in Hyannis

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →